Drug Prioritization Framework for Pharmacogenomics Studies in Saudi Arabia

2,035 real-world reports of adverse drug reactions or therapeutic inefficacy across 450 drugs inform a multi-criteria scoring framework. The framework, developed by Mustafa Adnan Malki, combines six weighted domains reflecting genetic plausibility and clinical significance. This Phase-1 initiative provides a structured approach for building locally relevant clinical pharmacogenomics evidence.

Use Cases

• Prioritizing drugs for clinical pharmacogenomics research based on real-world adverse drug reaction reports.
• Developing local clinical guidelines based on convergence between real-world signals and genetic data.
• Triangulating external evidence with a structured scoring framework to assess drug-gene associations.

Strengths

• Framework is based on 2,035 real-world reports of adverse drug reactions or therapeutic inefficacy.
• Analysis covers a broad scope of 450 drugs.
• Methodology includes sensitivity analyses and external evidence triangulation for robustness.

Limitations

• Dataset size is small at 250.4 KB, indicating limited scope.
• Row count and column-level documentation are unknown; field semantics must be inferred after download.
• Data may reflect geographic bias inherent to the Saudi Arabian healthcare context.

Provenance

Source

figshare

Collection Method

Analysis of real-world reports combined into a multi-criteria scoring framework.

Freshness

Last updated 2026-05-11 05:11:52; freshness should be verified.

Geography

Saudi Arabia